Skip to main content

Advertisement

SpringerLink
Log in

Trinucleotide repeat expansions in human breast cancer-susceptibility genes: relevant targets for aspirin chemoprevention?

  • Review Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

Defining novel molecular mechanisms pertinent to aspirin chemoprevention of breast cancer (BC) and to explain controversial epidemiological results in this regard.

Methods

Literature search in relevant databases with the following key words; aspirin, nucleotide repeat expansions, breast cancer. Human genome contains nucleotide repeat expansions and exon-1 of the androgen receptor gene AR contains a CAG string with an average of 20 repeats. Longer AR CAG repeats associate with lower AR protein functioning leading relatively higher estrogen receptor signals and higher risk of hormone receptor-positive BC. Nucleotide repeat expansions also exist in E2F4 and POLG genes in BC. In cell culture models, aspirin reduces CAG.CTG expansions in kidney cells and restores myogenic differentiation in cells obtained from tissues with myotonic dystrophy, a disorder caused by large CTG expansions.

Conclusions

We hypothesize that aspirin reduction of trinucleotide repeat expansions in breast cancer-susceptibility genes may be one of the relevant mechanisms of its chemopreventive effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Rajender S, Francis A, Pooja S, Krupakar N, Surekha D, Reddy G, et al. CAG repeat length polymorphism in the androgen receptor gene and breast cancer risk: data on Indian women and survey from the world. Breast Cancer Res Treat. 2011;127:751–60.

    Article  PubMed  Google Scholar 

  2. Elhaji YA, Gottlieb B, Lumbroso R, Beitel LK, Foulkes WD, et al. The polymorphic CAG repeat of the androgen receptor gene: a potential role in breast cancer in women over 40. Breast Cancer Res Treat. 2001;70:109–16.

    Article  PubMed  CAS  Google Scholar 

  3. Couture P, Thériault C, Simard J, Labrie F. Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Endocrinology. 1993;132:179–85.

    PubMed  CAS  Google Scholar 

  4. Boccuzzi G, Di Monaco M, Brignardello E, Leonardi L, Gatto V, Pizzini A, et al. Dehydroepiandrosterone antiestrogenic action through androgen receptor in MCF-7 human breast cancer cell line. Anticancer Res. 1993;13:2267–72.

    PubMed  CAS  Google Scholar 

  5. Szelei J, Jimenez J, Soto AM, Luizzi MF, Sonnenschein C. Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology. 1997;138:1406–12.

    PubMed  CAS  Google Scholar 

  6. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, et al. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer. 1991;67:886–91.

    Article  PubMed  CAS  Google Scholar 

  7. Thomas DB, Jimenez LM, McTiernan A, Rosenblatt K, Stalsberg H, Stemhagen A, et al. Breast cancer in men: risk factors with hormonal implications. Am J Epidemiol. 1992;135:734–48.

    PubMed  CAS  Google Scholar 

  8. Cutuli B, Dilhuydy JM, De Lafontan B, Berlie J, Lacroze M, Lesaunier F, et al. Ductal carcinoma in situ of the male breast. Analysis of 31 cases. Eur J Cancer. 1997;33:35–8.

    Article  PubMed  CAS  Google Scholar 

  9. Lapointe J, Fournier A, Richard V, Labrie C. Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells. Endocrinology. 1999;140:416–21.

    PubMed  CAS  Google Scholar 

  10. Li K, Chandra DP, Foo T, Adams JB, McDonald D. Steroid metabolism by human mammary carcinoma. Steroids. 1976;28:561–74.

    Article  PubMed  CAS  Google Scholar 

  11. Maggiolini M, Donzé O, Jeannin E, Andò S, Picard D. Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor alpha. Cancer Res. 1999;59:4864–9.

    PubMed  CAS  Google Scholar 

  12. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ. Androgen receptors in breast cancer. Cancer. 1984;54:2436–40.

    Article  PubMed  CAS  Google Scholar 

  13. Gatto V, Di Monaco M, Brignardello E, Leonardi L, Gallo M, Boccuzzi G. Indirect growth inhibition of the MDA-MB-231 hormone-independent breast cancer cell line by dihydrotestosterone. Ann N Y Acad Sci. 1996;784:439–42.

    Article  PubMed  CAS  Google Scholar 

  14. Zava DT, McGuire WL. Estrogen receptors in androgen-induced breast tumor regression. Cancer Res. 1977;37:1608–10.

    PubMed  CAS  Google Scholar 

  15. Poulin R, Baker D, Labrie F. Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat. 1988;12:213–25.

    Article  PubMed  CAS  Google Scholar 

  16. Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T, Rabe T. Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol. 2002;16:113–20.

    Article  PubMed  CAS  Google Scholar 

  17. Søreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol. 1992;18:112–8.

    PubMed  Google Scholar 

  18. Kuenen-Boumeester V, Van der Kwast TH, van Putten WL, Claassen C, van Ooijen B, Henzen-Logmans SC. Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. Int J Cancer. 1992;52:581–4.

    Article  PubMed  CAS  Google Scholar 

  19. Siiteri PK, Hammond GL, Nisker JA. Increased availability of serum estrogens in breast cancer: a new hypothesis. In: Pike MC, Siiteri PK, Welsch CW, editors. Hormones and breast cancer. Banbury Report No. 8. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1981. p. 87–101.

  20. Jarjanazi H, Li H, Andrulis IL, Ozcelik H. Genome wide screening of CAG trinucleotide repeat lengths in breast cancer. Dis Markers. 2006;22:343–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  21. Lee JH, Kim DK. Microsatellite instability of nuclear and mitochondrial DNAs in gastric carcinogenesis. Asian Pac J Cancer Prev. 2014;15(19):8029–32.

    Article  PubMed  Google Scholar 

  22. Gatchel JR, Zoghbi HY. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet. 2005;6:743–55.

    Article  PubMed  CAS  Google Scholar 

  23. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994;22:3181–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  24. Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR, Coetzee GA. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet. 2000;9:267–74.

    Article  PubMed  CAS  Google Scholar 

  25. Ferro P, Catalano MG, Dell’Eva R, Fortunati N, Pfeffer U. The androgen receptor CAG repeat: a modifier of carcinogenesis? Mol Cell Endocrinol. 2002;193:109–20.

    Article  PubMed  CAS  Google Scholar 

  26. Simanainen U, Brogley M, Gao YR, Jimenez M, Harwood DT, Handelsman DJ, et al. Length of the human androgen receptor glutamine tract determines androgen sensitivity in vivo. Mol Cell Endocrinol. 2011;342:81–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  27. Esteban E, Rodon N, Via M, Gonzalez-Perez E, Santamaria J, Dugoujon JM, et al. Androgen receptor CAG and GGC polymorphisms in Mediterraneans: repeat dynamics and population relationships. J Hum Genet. 2006;51:129–36.

    Article  PubMed  CAS  Google Scholar 

  28. Brinkmann AO, Faber PW, van Rooij HC, Kuiper GG, Ris C, Klaassen P, et al. The human androgen receptor: domain structure, genomic organization and regulation of expression. J Steroid Biochem. 1989;34:307–10.

    Article  PubMed  CAS  Google Scholar 

  29. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994;22:3181–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  30. Ding D, Xu L, Menon M, Reddy GP, Barrack ER. Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action. Prostate. 2005;62:133–9.

    Article  PubMed  CAS  Google Scholar 

  31. Wooster R, Mangion J, Eeles R, Smith S, Dowsett M, Averill D, et al. A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet. 1992;2:132–4.

    Article  PubMed  CAS  Google Scholar 

  32. Lobaccaro JM, Lumbroso S, Belon C, Galtier-Dereure F, Bringer J, Lesimple T, et al. Male breast cancer and the androgen receptor gene. Nat Genet. 1993;5:109–10.

    Article  PubMed  CAS  Google Scholar 

  33. Zhu X, Daffada AA, Chan CM, Dowsett M. Identification of an exon 3 deletion splice variant androgen receptor mRNA in human breast cancer. Int J Cancer. 1997;72:574–80.

    Article  PubMed  CAS  Google Scholar 

  34. Lillie EO, Bernstein L, Ursin G. The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer. Breast Cancer Res. 2003;5:164–73.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Trock BJ. Breast cancer in African American women: epidemiology and tumor biology. Breast Cancer Res Treat. 1996;40:11–24.

    Article  PubMed  CAS  Google Scholar 

  36. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics. 1992;12:241–53.

    Article  PubMed  CAS  Google Scholar 

  37. Irvine RA, Yu MC, Ross RK, Coetzee GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 1995;55:1937–40.

    PubMed  CAS  Google Scholar 

  38. Giguère Y, Dewailly E, Brisson J, Ayotte P, Laflamme N, Demers A, et al. Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population. Cancer Res. 2001;61:5869–74.

    PubMed  Google Scholar 

  39. Suter NM, Malone KE, Daling JR, Doody DR, Ostrander EA. Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women. Cancer Epidemiol Biomarkers Prev. 2003;12:127–35.

    PubMed  CAS  Google Scholar 

  40. Liede A, Zhang W, De Leon Matsuda ML, Tan A, Narod SA. Androgen receptor gene polymorphism and breast cancer susceptibility in The Philippines. Cancer Epidemiol Biomarkers Prev. 2003;12:848–52.

    PubMed  CAS  Google Scholar 

  41. Lillie EO, Bernstein L, Ingles SA, Gauderman WJ, Rivas GE, Gagalang V, et al. Polymorphism in the androgen receptor and mammographic density in women taking and not taking estrogen and progestin therapy. Cancer Res. 2004;64:1237–41.

    Article  PubMed  CAS  Google Scholar 

  42. Mehdipour P, Pirouzpanah S, Kheirollahi M, Atri M. Androgen receptor gene CAG repeat polymorphism and breast cancer risk in Iranian women: a case-control study. Breast J. 2011;17:39–46.

    Article  PubMed  CAS  Google Scholar 

  43. Anghel A, Raica M, Marian C, Ursoniu S, Mitrasca O. Combined profile of the tandem repeats CAG, TA and CA of the androgen and estrogen receptor genes in breast cancer. J Cancer Res Clin Oncol. 2006;132:727–33.

    Article  PubMed  CAS  Google Scholar 

  44. MacLean HE, Brown RW, Beilin J, Warne GL, Zajac JD. Increased frequency of long androgen receptor CAG repeats in male breast cancers. Breast Cancer Res Treat. 2004;88:239–46.

    Article  PubMed  CAS  Google Scholar 

  45. González A, Javier Dorta F, Rodriguez G, Brito B, Rodríguez MA, Cabrera A, et al. Increased risk of breast cancer in women bearing a combination of large CAG and GGN repeats in the exon 1 of the androgen receptor gene. Eur J Cancer. 2007;43:2373–80.

    Article  PubMed  Google Scholar 

  46. Wu MH, Chou YC, Yu CP, Yang T, You SL, Chen CJ, et al. Androgen receptor gene CAG repeats, estrogen exposure status, and breast cancer susceptibility. Eur J Cancer Prev. 2008;17:317–22.

    Article  PubMed  CAS  Google Scholar 

  47. Cox DG, Blanché H, Pearce CL, Calle EE, Colditz GA, Pike MC, et al. A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Breast Cancer Res. 2006;8(5):R54.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Gottlieb B, Alvarado C, Wang C, Gharizadeh B, Babrzadeh F, Richards B, et al. Making sense of intratumor genetic heterogeneity: altered frequency of androgen receptor CAG repeat length variants in breast cancer tissues. Hum Mutat. 2013;34:610–8.

    PubMed  CAS  Google Scholar 

  49. Dagan E, Friedman E, Paperna T, Carmi N, Gershoni-Baruch R. Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype. Eur J Hum Genet. 2002;10:724–8.

    Article  PubMed  CAS  Google Scholar 

  50. Kasami M, Gobbi H, Dupont WD, Simpson JF, Page DL, Vnencak-Jones CL. Androgen receptor CAG repeat lengths in ductal carcinoma in situ of breast, longest in apocrine variety. Breast. 2000;9:23–7.

    Article  PubMed  CAS  Google Scholar 

  51. Yu H, Bharaj B, Vassilikos EJ, Giai M, Diamandis EP. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Res Treat. 2000;59:153–61.

    Article  PubMed  CAS  Google Scholar 

  52. Spurdle AB, Antoniou AC, Duffy DL, Pandeya N, Kelemen L, Chen X, et al. The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2005;7:R176–83.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  53. Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet. 1999;64:1371–7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  54. De Abreu FB, Pirolo LJ, Canevari Rde A, Rosa FE, Moraes Neto FA, Caldeira JR, et al. Shorter CAG repeat in the AR gene is associated with atypical hyperplasia and breast carcinoma. Anticancer Res. 2007;27:1199–205.

    PubMed  Google Scholar 

  55. Haiman CA, Brown M, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, et al. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses’ Health Study. Cancer Res. 2002;62:1045–9.

    PubMed  CAS  Google Scholar 

  56. Wang W, John EM, Ingles SA. Androgen receptor and prostate-specific antigen gene polymorphisms and breast cancer in African-American women. Cancer Epidemiol Biomarkers Prev. 2005;14:2990–4.

    Article  PubMed  CAS  Google Scholar 

  57. Azrak S, Ayyasamy V, Zirpoli G, Ambrosone C, Bandera EV, Bovbjerg DH, et al. CAG repeat variants in the POLG1 gene encoding mtDNA polymerase-gamma and risk of breast cancer in African-American women. PLoS One. 2012;7:e29548. doi:10.1371/journal.pone.0029548.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  58. Singh KK, Ayyasamy V, Owens KM, Koul MS, Vujcic M. Mutations in mitochondrial DNA polymerase-gamma promote breast tumorigenesis. J Hum Genet. 2009;54:516–24.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  59. Pizzi C, Di Maio M, Daniele S, Mastranzo P, Spagnoletti I, Limite G, et al. Triplet repeat instability correlates with dinucleotide instability in primary breast cancer. Oncol Rep. 2007;17:193–9.

    PubMed  CAS  Google Scholar 

  60. Schwemmle S, Pfeifer GP. Genomic structure and mutation screening of the E2F4 gene in human tumors. Int J Cancer. 2000;86:672–7.

    Article  PubMed  CAS  Google Scholar 

  61. González-Hernández A, Henríquez-Hernández LA, Cabrera de León A, Rodríguez-Pérez Mdel C, Murias-Rosales A, Domínguez-Coello S, et al. Microsatellite polymorphisms in the EGFR, NOTCH4 and E2F4 genes and their association with breast cancer risk. Int J Biol Markers. 2012;27:e219–26.

    Article  PubMed  Google Scholar 

  62. Gomes-Pereira M, Monckton DG. Chemically induced increases and decreases in the rate of expansion of a CAG*CTG triplet repeat. Nucleic Acids Res. 2004;32:2865–72.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  63. Beaulieu D, Thebault P, Pelletier R, Chapdelaine P, Tarnopolsky M, Furling D, et al. Abnormal prostaglandin E2 production blocks myogenic differentiation in myotonic dystrophy. Neurobiol Dis. 2012;45:122–9.

    Article  PubMed  CAS  Google Scholar 

  64. Ready A, Velicer CM, McTiernan A, White E. NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat. 2008;109:533–43.

    Article  PubMed  CAS  Google Scholar 

  65. Mangiapane S, Blettner M, Schlattmann P. Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiol Drug Saf. 2008;17:115–24.

    Article  PubMed  Google Scholar 

  66. Agrawal A, Fentiman IS. NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract. 2008;62(3):444–9.

    Article  PubMed  CAS  Google Scholar 

  67. Gierach GL, Lacey JV Jr, Schatzkin A, Leitzmann MF, Richesson D, Hollenbeck AR, et al. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res. 2008;10:R38. doi:10.1186/bcr2089.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Takkouche B, Regueira-Méndez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst. 2008;100:1439–47.

    Article  PubMed  CAS  Google Scholar 

  69. Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes Control. 2011;22:965–75.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518–27.

    Article  PubMed  CAS  Google Scholar 

  71. Huang XZ, Gao P, Sun JX, Song YX, Tsai CC, Liu J, et al. Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis. Cancer Causes Control. 2015;26:589–600.

    Article  PubMed  Google Scholar 

  72. Barron TI, Murphy LM, Brown C, Bennett K, Visvanathan K, Sharp L. De novo post-diagnosis aspirin use and mortality in women with stage I-III breast cancer. Cancer Epidemiol Biomarkers Prev. 2015;24:898–904

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, Experimental Medicine Research Institute – DETAE, Istanbul University, Istanbul, Turkey

    M. A. Altinoz

  2. Department of Molecular Biology and Genetics, Halic University, Istanbul, Turkey

    N. E. Tunalı

Authors
  1. M. A. Altinoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. E. Tunalı
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. A. Altinoz.

Ethics declarations

Informed consent

Since the submitted article is a review study, no informed consents were needed.

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Altinoz, M.A., Tunalı, N.E. Trinucleotide repeat expansions in human breast cancer-susceptibility genes: relevant targets for aspirin chemoprevention?. Clin Transl Oncol 18, 9–17 (2016). https://doi.org/10.1007/s12094-015-1356-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-015-1356-1

Keywords

Search

Navigation